Holen Sie sich die Stockscreener-App
4.09
0.97%
-0.04
Handel nachbörslich:
4.07
-0.02
-0.49%
Aquestive Therapeutics Inc Aktie (AQST) Neueste Nachrichten
Bronstein, Gewirtz & Grossman LLC Urges Aquestive - globenewswire.com
AQST STOCKHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Aquestive Therapeutics, Inc. Investors with Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
2026-04-05 | AQST INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Reminds Stockholders of Aquestive Therapeutics, Inc. to Contact the Firm Today! | NDAQ:AQST | Press Release - Stockhouse
Published on: 2026-04-05 15:45:00 - baoquankhu1.vn
AQST INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Reminds Shareholders of Aquestive Therapeutics, Inc. to Contact the Firm Today! - ACCESS Newswire
AQST SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Reminds Aquestive Therapeutics (AQST) Investors of Securities Class Action Deadline on May 4, 2026 - prnewswire.com
Lake Street adjusts Aquestive Therapeutics, Inc. (AQST) valuation model on expected approval delay - MSN
Bernstein Liebhard LLP Reminds Aquestive Shareholders of Lawsuit - National Today
AQUESTIVE THERAPEUTICS, INC. (AQST) SHAREHOLDER ALERT Bernstein Liebhard LLP Reminds Aquestive ... - bdtonline.com
AQUESTIVE THERAPEUTICS, INC. (AQST) SHAREHOLDER ALERT - GlobeNewswire
AQST SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Reminds Aquestive Therapeutics (AQST) ... - bdtonline.com
AQST SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Reminds - GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Aquestive Therapeutics, Inc. of Class Action Lawsuit and Upcoming DeadlinesAQST - prnewswire.com
AQST INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Reminds Investors of Aquestive Therapeutics, Inc. to Contact the Firm Today! - ACCESS Newswire
AQST Stock Price, Quote & Chart | AQUESTIVE THERAPEUTICS INC (NASDAQ:AQST) - ChartMill
Aquestive Therapeutics, Inc. (AQST) stock price, news, quote and history - Yahoo Finance UK
AQST Investors Have Opportunity to Lead Aquestive Therapeutics, Inc. Securities Fraud Lawsuit - ChartMill
AQST Stockholders Have Opportunity to Lead Aquestive Therapeutics, Inc. Class Action Lawsuit – Contact Bronstein, Gewirtz and Grossman, LLC Today! - ACCESS Newswire
ROSEN, LEADING INVESTOR COUNSEL, Encourages Aquestive Therapeutics, Inc. Investors to Secure ... - Caledonian Record
ROSEN, LEADING INVESTOR COUNSEL, Encourages Aquestive - GlobeNewswire
AQST Investor Alert: AQUESTIVE THERAPEUTICS, INC. Securities Fraud LawsuitInvestors With Losses May Seek to Lead the Class Action After Analyst Slashed Price Target: Levi & Korsinsky - prnewswire.com
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Aquestive Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadlines – AQST - ChartMill
User - The Chronicle-Journal
Aquestive Therapeutics Faces Investor Lawsuit Over Alleged Misleading Statements About Anaphylm FDA Approval Timeline - tipranks.com
Analysts Offer Insights on Healthcare Companies: Aquestive Therapeutics (AQST) and Insmed (INSM) - The Globe and Mail
AQST Stockholders Have Rights – If You Lost Money Investing - globenewswire.com
AQST Shareholders Have Opportunity to Lead Aquestive Therapeutics, Inc. Class Action Lawsuit – Contact Bronstein, Gewirtz and Grossman, LLC Today! - ACCESS Newswire
SHAREHOLDER ALERT Bernstein Liebhard LLP Announces A Securities Fraud Class Action Lawsuit Has Been Filed Against Aquestive Therapeutics, Inc. (AQST) - TMX Newsfile
Analysts Are Bullish on These Healthcare Stocks: Alumis Inc. (ALMS), Aquestive Therapeutics (AQST) - The Globe and Mail
AQST Shareholder Alert: Investors With Losses May Seek to Lead the Class Action in Aquestive Therapeutics, Inc. Securities Lawsuit — The Gross Law Firm - Morningstar
SHAREHOLDER ALERT Bernstein Liebhard LLP Announces A - globenewswire.com
Aquestive Therapeutics (AQST) Awaits Anaphylm NDA Approval in Q3 - Insider Monkey
ROSEN, LEADING INVESTOR COUNSEL, Encourages Aquestive Therapeutic - The National Law Review
AQST PE Ratio & Valuation, Is AQST Overvalued - Intellectia AI
AQST Investors Have Opportunity to Lead Aquestive Therapeutics, Inc. Class Action Lawsuit – Contact Bronstein, Gewirtz and Grossman, LLC Today! - ACCESS Newswire
AQST Investor Alert: Aquestive Therapeutics Faces Securities Fraud Lawsuit - National Today
Bragar Eagel & Squire Urges Aquestive Investors to Contact Firm Before Deadline - National Today
Bragar Eagel & Squire, P.C. Reminds Aquestive Therapeutics, Inc. Investors with Significant ... - bdtonline.com
Bragar Eagel & Squire, P.C. Reminds Aquestive Therapeutics, Inc. Investors with Significant Losses to Contact the Firm Before Upcoming Lead Plaintiff Deadline - The Norfolk Daily News
AQST Investor Alert: AQUESTIVE THERAPEUTICS, INC. - globenewswire.com
Aquestive Therapeutics Completes FDA Type A Meeting for Anaphylm, Plans NDA Resubmission in Q3 2026 - Minichart
Aquestive Advances Anaphylm NDA Resubmission After FDA Meeting - TipRanks
Aquestive Therapeutics | 8-K: Current report - Moomoo
Aquestive Therapeutics Receives FDA's Preliminary Comments on Anaphylm Study Designs - marketscreener.com
Aquestive reaffirms Q3 2026 NDA resubmission for Anaphylm By Investing.com - Investing.com Canada
Aquestive completes Type A FDA meeting, reaffirms Q3 2026 Anaphylm NDA resubmission - TradingView
FDA Type A meeting guides Aquestive (NASDAQ: AQST) Anaphylm NDA path - Stock Titan
Aquestive Therapeutics Announces Completion of Type A Meeting with FDA for Anaphylm™ (dibutepinephrine) Sublingual Film - Yahoo Finance
AQST Stock Chart | AQUESTIVE THERAPEUTICS INC (NASDAQ:AQST) - ChartMill
ROSEN Law Firm Urges Aquestive Therapeutics Investors to Seek Legal Counsel - National Today
ROSEN, THE FIRST FILING FIRM, Encourages Franklin BSP Realty Trust, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm – FBRT - GlobeNewswire Inc.
ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Aquestive Therapeutics, Inc. Investors to Secure ... - Caledonian Record
ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Aquestive - GlobeNewswire
AQST SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Aquestive Therapeutics, Inc. Stockholders Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
AQST DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds Aquestive Therapeutics Investors of Securities Class Action Deadline on May 4, 2026 - ChartMill
AQST Shareholder Alert: Aquestive Therapeutics, Inc. Securities Class Action Lawsuit Investors ... - Bluefield Daily Telegraph
AQST Shareholder Alert: Aquestive Therapeutics, Inc. - GlobeNewswire
AQST INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Aquestive Therapeutics, Inc. Stockholders Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
Lawsuit Alert: Investors who lost money with shares of Aquestive - openPR.com
ROSEN, TOP RANKED GLOBAL INVESTOR COUNSEL, Encourages Aquestive Therapeutics, Inc. Investors to ... - Caledonian Record
ROSEN, TOP RANKED GLOBAL INVESTOR COUNSEL, Encourages - GlobeNewswire
AQST Lawsuit Alleges Allegedly Concealed Anaphylm NDA Deficienci - GuruFocus
AQST INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Aquestive Therapeutics, Inc. Shareholders Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
AQST Lawsuit Alleges Allegedly Concealed Anaphylm NDA DeficienciesAQUESTIVE THERAPEUTICS, INC. Investors Face Losses Following Allegedly Concealed Anaphylm NDA Deficiencies: SueWallSt - ChartMill
AQST SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Aquestive Therapeutics, Inc. Investors Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
AQST INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Reminds Aquestive Therapeutics ... - Bluefield Daily Telegraph
AQST INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Reminds Aquestive Therapeutics Investors of Securities Class Action Deadline on May 4, 2026 - ChartMill
1.35%
0.67%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):